Filing summary
Entity note: The request identifies Cibus, Inc., but the supplied Form 10-K is for Calyxt, Inc. (NASDAQ: CLXT). This summary covers the filing provided, for the fiscal year ended December 31, 2020, not a standalone fourth quarter.
Business context and reporting period
Calyxt is an early-stage agricultural technology company developing gene-edited crops and plant-based products. Its business model shifted toward seed sales, trait development and licensing, and technology licensing, with commercial partners expected to handle much of downstream commercialization. Cellectis owned 64.7% of Calyxt at year-end.
In August 2020, Calyxt changed its high-oleic soybean strategy: it stopped marketing soybean oil and meal and planned to sell grain during 2021, then transition to seed sales. At year-end, its pipeline included nine candidates at Phase 1 or later, across alfalfa, wheat, soybeans, hemp, and oats.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $23.9 million | $7.3 million |
| Gross margin | $(11.3) million; negative 47% | $(2.0) million; negative 27% |
| Operating expenses | $32.6 million | $37.7 million |
| Net loss | $(44.8) million | $(39.6) million |
| Basic and diluted loss per share | $(1.32) | $(1.21) |
| Adjusted EBITDA, non-GAAP | $(31.6) million | $(29.8) million |
| Net cash used in operating activities | $(43.7) million | $(32.0) million |
- Revenue rose 227%, driven by soybean grain sales and completion of oil and meal sales. Soybean grain contributed $13.0 million; oil and meal contributed $10.8 million combined.
- Cost of goods sold increased to $35.1 million. The filing cites higher sales volume and grain prices, $2.8 million of unrealized commodity-hedge losses, and $1.3 million in inventory valuation adjustments, including excess seed write-downs.
- Cash, cash equivalents, restricted cash, and short-term investments totaled approximately $30.0 million at year-end, versus $60.0 million a year earlier. Current liabilities were $6.9 million; current assets were $39.6 million.
- Year-end liabilities included $17.9 million of financing lease obligations and a $1.5 million Paycheck Protection Program loan. The filing also lists $21.2 million of forward purchase commitments, all payable in 2021 based on year-end estimates.
- In October 2020, the company raised $14.0 million net through a follow-on stock offering. It reported $1.5 million of PPP loan proceeds and had applied for forgiveness of the principal and accrued interest; forgiveness was not assured.
Material changes, outlook, and risks
- Management estimated available cash and investments would fund operations into the second half of 2022, while warning that longer-term needs would require additional capital. The company expected 2021 operating cash use to be below 2020 and selling and supply-chain expenses to decline significantly, while anticipating mid-single-digit growth in cash R&D expenses over time.
- All 2020 soybean crop grain was contracted to ADM, with deliveries and sales expected through 2021. Pricing was to be based on agricultural commodity market prices when delivery pricing was agreed, so realized revenue and margins remained exposed to market conditions.
- High-fiber wheat field trials were damaged by improper aerial chemical applications by unaffiliated third parties. Development was delayed by at least one year; commercial availability was uncertain and not expected before 2023. Calyxt said it was pursuing available avenues of recourse.
- The improved-digestibility alfalfa candidate was targeted for commercial launch in 2021 through an exclusive license with S&W Seed, subject to field trials, testing, and regulatory consultation. Management targeted at least five candidates for commercial planting from 2021 through 2024.
- CEO James Blome’s departure and Yves Ribeill’s appointment as Executive Chair and interim principal executive officer occurred in February 2021, after the reporting period. Calyxt expected up to $2.3 million of cash separation expense in Q1 2021, partly offset in earnings by a $2.5 million non-cash stock-compensation recapture.
- Key risks include continued losses and financing needs; execution of the new business model and dependence on partners; crop, field-trial, supply-chain, and commodity-price risks; evolving gene-editing regulation and market acceptance; competition; and reliance on licensed intellectual property. Cellectis’ majority ownership and contractual rights limit other stockholders’ influence.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is Calyxt, Inc., not Cibus, Inc.
- Review audited financial statements and reconcile reported liquidity, cash burn, and the estimated runway against planned operating costs and financing needs.
- Track actual ADM grain deliveries, market-based pricing, hedge results, and final gross margins as the soybean business transitions to seed sales.
- Check the status and terms of PPP loan forgiveness and the 2021 forward-purchase commitments.
- Monitor wheat trial recovery and alfalfa launch progress, including partner execution and required testing or regulatory steps.
- Assess the effect of the CEO transition and Cellectis’ control, including related-party and intellectual-property licensing arrangements.